{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:21:54Z","timestamp":1777616514896,"version":"3.51.4"},"publisher-location":"Cham","reference-count":291,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030963750","type":"print"},{"value":"9783030963767","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-030-96376-7_3","type":"book-chapter","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:13:39Z","timestamp":1652346819000},"page":"91-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity"],"prefix":"10.1007","author":[{"given":"Michael","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"5","key":"3_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ni921","volume":"4","author":"KA Fitzgerald","year":"2003","unstructured":"Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT et al (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4(5):491\u2013496. https:\/\/doi.org\/10.1038\/ni921","journal-title":"Nat Immunol"},{"issue":"11","key":"3_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","volume":"13","author":"T Kawai","year":"2007","unstructured":"Kawai T, Akira S (2007) Signaling to NF-kappaB by toll-like receptors. Trends Mol Med 13(11):460\u2013469. https:\/\/doi.org\/10.1016\/j.molmed.2007.09.002","journal-title":"Trends Mol Med"},{"issue":"3","key":"3_CR3","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2020.20.e21","volume":"20","author":"F Fore","year":"2020","unstructured":"Fore F, Indriputri C, Mamutse J, Nugraha J (2020) TLR10 and Its unique anti-inflammatory properties and potential use as a target in therapeutics. Immune Netw. 20(3):e21. https:\/\/doi.org\/10.4110\/in.2020.20.e21","journal-title":"Immune Netw."},{"issue":"27","key":"3_CR4","doi-asserted-by":"publisher","first-page":"15778","DOI":"10.1073\/pnas.1921861117","volume":"117","author":"K Esser-Nobis","year":"2020","unstructured":"Esser-Nobis K, Hatfield LD, Gale M Jr (2020) Spatiotemporal dynamics of innate immune signaling via RIG-I-like receptors. Proc Natl Acad Sci USA 117(27):15778\u201315788. https:\/\/doi.org\/10.1073\/pnas.1921861117","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2006.04.017","volume":"25","author":"RS Allan","year":"2006","unstructured":"Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y et al (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25(1):153\u2013162. https:\/\/doi.org\/10.1016\/j.immuni.2006.04.017","journal-title":"Immunity"},{"issue":"6","key":"3_CR6","doi-asserted-by":"publisher","first-page":"e11144","DOI":"10.1371\/journal.pone.0011144","volume":"5","author":"AW Yewdall","year":"2010","unstructured":"Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N (2010) CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE 5(6):e11144. https:\/\/doi.org\/10.1371\/journal.pone.0011144","journal-title":"PLoS ONE"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3389\/fimmu.2018.02472","volume":"9","author":"J Grabowska","year":"2018","unstructured":"Grabowska J, Lopez-Venegas MA, Affandi AJ, den Haan JMM (2018) CD169(+) macrophages capture and dendritic cells instruct: the interplay of the gatekeeper and the general of the immune system. Front Immunol 9:2472. https:\/\/doi.org\/10.3389\/fimmu.2018.02472","journal-title":"Front Immunol"},{"key":"3_CR8","unstructured":"Janeway CA Jr TP, Walport M, Shlomchik MJ (2001) Immunobiology. Garland Science, New York"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104803","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"3_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"11","key":"3_CR12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/15200","volume":"5","author":"S Gallucci","year":"1999","unstructured":"Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5(11):1249\u20131255. https:\/\/doi.org\/10.1038\/15200","journal-title":"Nat Med"},{"issue":"7","key":"3_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE et al (2015) Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11(7):1018\u20131030. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.031","journal-title":"Cell Rep"},{"issue":"7","key":"3_CR14","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1172\/JCI86892","volume":"126","author":"L Corrales","year":"2016","unstructured":"Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF (2016) The host STING pathway at the interface of cancer and immunity. J Clin Invest 126(7):2404\u20132411. https:\/\/doi.org\/10.1172\/JCI86892","journal-title":"J Clin Invest"},{"issue":"9","key":"3_CR15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050\u20131059. https:\/\/doi.org\/10.1038\/nm1622","journal-title":"Nat Med"},{"issue":"2","key":"3_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","volume":"123","author":"SJ Gardai","year":"2005","unstructured":"Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123(2):321\u2013334. https:\/\/doi.org\/10.1016\/j.cell.2005.08.032","journal-title":"Cell"},{"issue":"1","key":"3_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523","journal-title":"Nat Med"},{"issue":"63","key":"3_CR18","doi-asserted-by":"publisher","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J et al (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2(63):63ra94. https:\/\/doi.org\/10.1126\/scitranslmed.3001375","journal-title":"Sci Transl Med"},{"issue":"2","key":"3_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.164.2.558","volume":"164","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164(2):558\u2013561. https:\/\/doi.org\/10.4049\/jimmunol.164.2.558","journal-title":"J Immunol"},{"issue":"33","key":"3_CR20","doi-asserted-by":"publisher","first-page":"31332","DOI":"10.1074\/jbc.M103217200","volume":"276","author":"RM Vabulas","year":"2001","unstructured":"Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H et al (2001) Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll\/IL-1 receptor signaling pathway in innate immune cells. J Biol Chem 276(33):31332\u201331339. https:\/\/doi.org\/10.1074\/jbc.M103217200","journal-title":"J Biol Chem"},{"issue":"17","key":"3_CR21","doi-asserted-by":"publisher","first-page":"15107","DOI":"10.1074\/jbc.M111204200","volume":"277","author":"RM Vabulas","year":"2002","unstructured":"Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H (2002) HSP70 as endogenous stimulus of the toll\/IL-1 receptor signal pathway. J Biol Chem 277(17):15107\u201315112. https:\/\/doi.org\/10.1074\/jbc.M111204200","journal-title":"J Biol Chem"},{"issue":"17","key":"3_CR22","doi-asserted-by":"publisher","first-page":"15028","DOI":"10.1074\/jbc.M200497200","volume":"277","author":"A Asea","year":"2002","unstructured":"Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE et al (2002) Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 277(17):15028\u201315034. https:\/\/doi.org\/10.1074\/jbc.M200497200","journal-title":"J Biol Chem"},{"issue":"6","key":"3_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1161\/hc0602.103617","volume":"105","author":"B Dybdahl","year":"2002","unstructured":"Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N et al (2002) Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105(6):685\u2013690. https:\/\/doi.org\/10.1161\/hc0602.103617","journal-title":"Circulation"},{"issue":"11","key":"3_CR24","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.4049\/jimmunol.176.11.7021","volume":"176","author":"MF Roelofs","year":"2006","unstructured":"Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU et al (2006) Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 176(11):7021\u20137027. https:\/\/doi.org\/10.4049\/jimmunol.176.11.7021","journal-title":"J Immunol"},{"issue":"1\u20132","key":"3_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"issue":"11","key":"3_CR26","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1172\/JCI121476","volume":"128","author":"CC Smith","year":"2018","unstructured":"Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ et al (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128(11):4804\u20134820. https:\/\/doi.org\/10.1172\/JCI121476","journal-title":"J Clin Invest"},{"issue":"10","key":"3_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1164\/rccm.200808-1274OC","volume":"179","author":"P Gasse","year":"2009","unstructured":"Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V et al (2009) Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 179(10):903\u2013913. https:\/\/doi.org\/10.1164\/rccm.200808-1274OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3_CR28","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/art.21238","volume":"52","author":"R Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R (2005) Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 52(9):2936\u20132946. https:\/\/doi.org\/10.1002\/art.21238","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1084\/jem.20071087","volume":"205","author":"M Kool","year":"2008","unstructured":"Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S et al (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205(4):869\u2013882. https:\/\/doi.org\/10.1084\/jem.20071087","journal-title":"J Exp Med"},{"issue":"6494","key":"3_CR30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT et al (2020) The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368(6494):973\u2013980. https:\/\/doi.org\/10.1126\/science.aay9189","journal-title":"Science"},{"key":"3_CR31","doi-asserted-by":"publisher","unstructured":"Dohlman AB, Arguijo Mendoza D, Ding S, Gao M, Dressman H, Iliev ID, et al (2021) The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. Cell Host Microbe 29(2):281\u2013298 e5. https:\/\/doi.org\/10.1016\/j.chom.2020.12.001","DOI":"10.1016\/j.chom.2020.12.001"},{"issue":"18 Pt 1","key":"3_CR32","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-07-1030","volume":"13","author":"X Zang","year":"2007","unstructured":"Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18 Pt 1):5271\u20135279. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1030","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-065X.2009.00771.x","volume":"229","author":"G Driessens","year":"2009","unstructured":"Driessens G, Kline J, Gajewski TF (2009) Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 229(1):126\u2013144. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00771.x","journal-title":"Immunol Rev"},{"issue":"938","key":"3_CR34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","volume":"79","author":"SA Hoption Cann","year":"2003","unstructured":"Hoption Cann SA, van Netten JP, van Netten C (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79(938):672\u2013680","journal-title":"Postgrad Med J"},{"issue":"Surg Sect","key":"3_CR35","first-page":"1","volume":"3","author":"WB Coley","year":"1910","unstructured":"Coley WB (1910) The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 3(Surg Sect):1\u201348","journal-title":"Proc R Soc Med"},{"issue":"8","key":"3_CR36","first-page":"824","volume":"111","author":"R Jackson","year":"1974","unstructured":"Jackson R (1974) Saint Peregrine, O.S.M.\u2014the patron saint of cancer patients. Can Med Assoc J. 111(8):824","journal-title":"Can Med Assoc J."},{"issue":"2","key":"3_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1054\/mehy.2001.1469","volume":"58","author":"SA Hoption Cann","year":"2002","unstructured":"Hoption Cann SA, van Netten JP, van Netten C, Glover DW (2002) Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 58(2):115\u2013119. https:\/\/doi.org\/10.1054\/mehy.2001.1469","journal-title":"Med Hypotheses"},{"issue":"922","key":"3_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/pmj.78.922.449","volume":"78","author":"JP Meyer","year":"2002","unstructured":"Meyer JP, Persad R, Gillatt DA (2002) Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J 78(922):449\u2013454. https:\/\/doi.org\/10.1136\/pmj.78.922.449","journal-title":"Postgrad Med J"},{"key":"3_CR39","first-page":"97","volume":"9","author":"R Peral","year":"1929","unstructured":"Peral R (1929) Cancer and tuberculosis. Am J Hyg 9:97\u2013159","journal-title":"Am J Hyg"},{"issue":"7597","key":"3_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s0140-6736(69)92648-8","volume":"1","author":"G Mathe","year":"1969","unstructured":"Mathe G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR et al (1969) Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1(7597):697\u2013699. https:\/\/doi.org\/10.1016\/s0140-6736(69)92648-8","journal-title":"Lancet"},{"issue":"2","key":"3_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180\u2013183. https:\/\/doi.org\/10.1016\/s0022-5347(17)58737-6","journal-title":"J Urol"},{"issue":"1","key":"3_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124(1):38\u201340. https:\/\/doi.org\/10.1016\/s0022-5347(17)55282-9","journal-title":"J Urol"},{"issue":"3","key":"3_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective. Nat Rev Urol 11(3):153\u2013162. https:\/\/doi.org\/10.1038\/nrurol.2014.15","journal-title":"Nat Rev Urol"},{"issue":"8187","key":"3_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(80)90057-4","volume":"2","author":"J Lacour","year":"1980","unstructured":"Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G et al (1980) Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet 2(8187):161\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(80)90057-4","journal-title":"Lancet"},{"issue":"23\u201324","key":"3_CR45","first-page":"912","volume":"46","author":"M Pawlicki","year":"1993","unstructured":"Pawlicki M, Jonca M, Krzemieniecki K, Zuchowska-Vogelgesang B (1993) Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation. Wiad Lek 46(23\u201324):912\u2013914","journal-title":"Wiad Lek"},{"issue":"6","key":"3_CR46","first-page":"599","volume":"18","author":"J Lacour","year":"1992","unstructured":"Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N et al (1992) Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1\/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 18(6):599\u2013604","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"3_CR47","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20090247","volume":"206","author":"MP Longhi","year":"2009","unstructured":"Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C et al (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206(7):1589\u20131602. https:\/\/doi.org\/10.1084\/jem.20090247","journal-title":"J Exp Med"},{"issue":"7","key":"3_CR48","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1073\/pnas.0711976105","volume":"105","author":"C Trumpfheller","year":"2008","unstructured":"Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y et al (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105(7):2574\u20132579. https:\/\/doi.org\/10.1073\/pnas.0711976105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3_CR49","doi-asserted-by":"publisher","unstructured":"Sultan H, Wu J, Fesenkova VI, Fan AE, Addis D, Salazar AM, et al (2020) Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J Immunother Cancer 8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001224","DOI":"10.1136\/jitc-2020-001224"},{"issue":"7","key":"3_CR50","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00262-018-2164-6","volume":"67","author":"H Sultan","year":"2018","unstructured":"Sultan H, Wu J, Kumai T, Salazar AM, Celis E (2018) Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice. Cancer Immunol Immunother 67(7):1091\u20131103. https:\/\/doi.org\/10.1007\/s00262-018-2164-6","journal-title":"Cancer Immunol Immunother"},{"key":"3_CR51","doi-asserted-by":"crossref","unstructured":"Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, et al (1996) Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38(6):1096\u20131103; discussion 103\u2013104","DOI":"10.1227\/00006123-199606000-00006"},{"issue":"2","key":"3_CR52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1078-0432.CCR-14-1790","volume":"21","author":"H Okada","year":"2015","unstructured":"Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ et al (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21(2):286\u2013294. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1790","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3_CR53","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","volume":"2","author":"AM Salazar","year":"2014","unstructured":"Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB (2014) Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2(8):720\u2013724. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0024","journal-title":"Cancer Immunol Res"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/JHC.S136652","volume":"4","author":"AN de la Torre","year":"2017","unstructured":"de la Torre AN, Contractor S, Castaneda I, Cathcart CS, Razdan D, Klyde D et al (2017) A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma 4:111\u2013121. https:\/\/doi.org\/10.2147\/JHC.S136652","journal-title":"J Hepatocell Carcinoma"},{"issue":"20","key":"3_CR55","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","volume":"24","author":"C Kyi","year":"2018","unstructured":"Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J et al (2018) Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. Clin Cancer Res 24(20):4937\u20134948. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1866","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3_CR56","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S et al (2019) Systemic clinical tumor regressions and potentiation of PD-1 blockade with in situ vaccination. Nat Med 25(5):814\u2013824. https:\/\/doi.org\/10.1038\/s41591-019-0410-x","journal-title":"Nat Med"},{"issue":"3","key":"3_CR57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM et al (2021) Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27(3):515\u2013525. https:\/\/doi.org\/10.1038\/s41591-020-01206-4","journal-title":"Nat Med"},{"issue":"5","key":"3_CR58","first-page":"461","volume":"4","author":"M Shear","year":"1944","unstructured":"Shear M, Perrault A (1944) Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J National Cancer Inst 4(5):461\u2013476","journal-title":"J National Cancer Inst"},{"issue":"6","key":"3_CR59","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00001813-200307000-00012","volume":"14","author":"EK Won","year":"2003","unstructured":"Won EK, Zahner MC, Grant EA, Gore P, Chicoine MR (2003) Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme. Anticancer Drugs 14(6):457\u2013466. https:\/\/doi.org\/10.1097\/00001813-200307000-00012","journal-title":"Anticancer Drugs"},{"key":"3_CR60","doi-asserted-by":"publisher","unstructured":"Chicoine MR, Won EK, Zahner MC (2001) Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery 48(3):607\u2013614; discussion 14\u201315. https:\/\/doi.org\/10.1097\/00006123-200103000-00032","DOI":"10.1097\/00006123-200103000-00032"},{"issue":"6","key":"3_CR61","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1084\/jem.148.6.1560","volume":"148","author":"MJ Berendt","year":"1978","unstructured":"Berendt MJ, North RJ, Kirstein DP (1978) The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med 148(6):1560\u20131569. https:\/\/doi.org\/10.1084\/jem.148.6.1560","journal-title":"J Exp Med"},{"issue":"10","key":"3_CR62","first-page":"2524","volume":"51","author":"R Engelhardt","year":"1991","unstructured":"Engelhardt R, Mackensen A, Galanos C (1991) Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51(10):2524\u20132530","journal-title":"Cancer Res"},{"issue":"10","key":"3_CR63","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/0959-8049(96)00186-4","volume":"32A","author":"F Otto","year":"1996","unstructured":"Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M et al (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A(10):1712\u20131718. https:\/\/doi.org\/10.1016\/0959-8049(96)00186-4","journal-title":"Eur J Cancer"},{"issue":"3","key":"3_CR64","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0161-5890(85)90164-6","volume":"22","author":"DK Ha","year":"1985","unstructured":"Ha DK, Leung SW, Fung KP, Choy YM, Lee CY (1985) Role of lipid A of endotoxin in the production of tumour necrosis factor. Mol Immunol 22(3):291\u2013294. https:\/\/doi.org\/10.1016\/0161-5890(85)90164-6","journal-title":"Mol Immunol"},{"issue":"1","key":"3_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3181\/00379727-136-35194","volume":"136","author":"A Nowotny","year":"1971","unstructured":"Nowotny A, Golub S, Key B (1971) Fate and effect of endotoxin derivtives in tumor-bearing mice. Proc Soc Exp Biol Med 136(1):66\u201369. https:\/\/doi.org\/10.3181\/00379727-136-35194","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"3_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF00205743","volume":"18","author":"GJ Vosika","year":"1984","unstructured":"Vosika GJ, Barr C, Gilbertson D (1984) Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 18(2):107\u2013112. https:\/\/doi.org\/10.1007\/BF00205743","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3_CR67","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/onci.20931","volume":"1","author":"E Vacchelli","year":"2012","unstructured":"Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C et al (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1(6):894\u2013907. https:\/\/doi.org\/10.4161\/onci.20931","journal-title":"Oncoimmunology."},{"issue":"2","key":"3_CR68","first-page":"397","volume":"6","author":"JS de Bono","year":"2000","unstructured":"de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D et al (2000) Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6(2):397\u2013405","journal-title":"Clin Cancer Res"},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2407-13-172","volume":"13","author":"N Isambert","year":"2013","unstructured":"Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J et al (2013) Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 13:172. https:\/\/doi.org\/10.1186\/1471-2407-13-172","journal-title":"BMC Cancer"},{"issue":"1","key":"3_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1470-2045(11)70324-2","volume":"13","author":"M Schiffman","year":"2012","unstructured":"Schiffman M, Wacholder S (2012) Success of HPV vaccination is now a matter of coverage. Lancet Oncol 13(1):10\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(11)70324-2","journal-title":"Lancet Oncol"},{"issue":"5","key":"3_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.2018.36.5_suppl.71","volume":"36","author":"YD Seo","year":"2018","unstructured":"Seo YD, Zhou J, Morse K, Patino J, Mackay S, Kim EY et al (2018) Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically. J Clin Oncol 36(5):71","journal-title":"J Clin Oncol"},{"issue":"11","key":"3_CR72","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","volume":"15","author":"MA Shetab Boushehri","year":"2018","unstructured":"Shetab Boushehri MA, Lamprecht A (2018) TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings. Mol Pharm 15(11):4777\u20134800. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00691","journal-title":"Mol Pharm"},{"issue":"5","key":"3_CR73","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1128\/AAC.32.5.678","volume":"32","author":"M Chen","year":"1988","unstructured":"Chen M, Griffith BP, Lucia HL, Hsiung GD (1988) Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 32(5):678\u2013683. https:\/\/doi.org\/10.1128\/AAC.32.5.678","journal-title":"Antimicrob Agents Chemother"},{"issue":"4\u20135","key":"3_CR74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0166-3542(88)90032-0","volume":"10","author":"CJ Harrison","year":"1988","unstructured":"Harrison CJ, Jenski L, Voychehovski T, Bernstein DI (1988) Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 10(4\u20135):209\u2013223. https:\/\/doi.org\/10.1016\/0166-3542(88)90032-0","journal-title":"Antiviral Res"},{"issue":"9","key":"3_CR75","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1128\/AAC.33.9.1511","volume":"33","author":"DI Bernstein","year":"1989","unstructured":"Bernstein DI, Harrison CJ (1989) Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother 33(9):1511\u20131515. https:\/\/doi.org\/10.1128\/AAC.33.9.1511","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3_CR76","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0166-3542(91)90012-g","volume":"15","author":"CJ Harrison","year":"1991","unstructured":"Harrison CJ, Stanberry LR, Bernstein DI (1991) Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs. Antiviral Res 15(4):315\u2013322. https:\/\/doi.org\/10.1016\/0166-3542(91)90012-g","journal-title":"Antiviral Res"},{"issue":"3","key":"3_CR77","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/infdis\/167.3.731","volume":"167","author":"DI Bernstein","year":"1993","unstructured":"Bernstein DI, Miller RL, Harrison CJ (1993) Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 167(3):731\u2013735. https:\/\/doi.org\/10.1093\/infdis\/167.3.731","journal-title":"J Infect Dis"},{"issue":"1","key":"3_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0166-3542(93)90058-q","volume":"20","author":"DI Bernstein","year":"1993","unstructured":"Bernstein DI, Miller RL, Harrison CJ (1993) Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res 20(1):45\u201355. https:\/\/doi.org\/10.1016\/0166-3542(93)90058-q","journal-title":"Antiviral Res"},{"issue":"2","key":"3_CR79","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jlb.55.2.234","volume":"55","author":"MJ Reiter","year":"1994","unstructured":"Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA (1994) Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 55(2):234\u2013240. https:\/\/doi.org\/10.1002\/jlb.55.2.234","journal-title":"J Leukoc Biol"},{"issue":"6","key":"3_CR80","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/jir.1995.15.537","volume":"15","author":"SJ Gibson","year":"1995","unstructured":"Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL et al (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15(6):537\u2013545. https:\/\/doi.org\/10.1089\/jir.1995.15.537","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"3_CR81","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1128\/MCB.15.4.2207","volume":"15","author":"K Megyeri","year":"1995","unstructured":"Megyeri K, Au WC, Rosztoczy I, Raj NB, Miller RL, Tomai MA et al (1995) Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 15(4):2207\u20132218. https:\/\/doi.org\/10.1128\/MCB.15.4.2207","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3_CR82","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jlb.58.3.365","volume":"58","author":"TL Testerman","year":"1995","unstructured":"Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ et al (1995) Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58(3):365\u2013372. https:\/\/doi.org\/10.1002\/jlb.58.3.365","journal-title":"J Leukoc Biol"},{"issue":"21","key":"3_CR83","first-page":"5176","volume":"53","author":"PL Witt","year":"1993","unstructured":"Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE et al (1993) Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53(21):5176\u20135180","journal-title":"Cancer Res"},{"issue":"9","key":"3_CR84","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/bjc.1996.569","volume":"74","author":"P Savage","year":"1996","unstructured":"Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME (1996) A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 74(9):1482\u20131486. https:\/\/doi.org\/10.1038\/bjc.1996.569","journal-title":"Br J Cancer"},{"issue":"4","key":"3_CR85","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1067\/mjd.2002.123492","volume":"47","author":"AN Persaud","year":"2002","unstructured":"Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C et al (2002) Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 47(4):553\u2013556. https:\/\/doi.org\/10.1067\/mjd.2002.123492","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1067\/mjd.2002.126257","volume":"47","author":"SJ Salasche","year":"2002","unstructured":"Salasche SJ, Levine N, Morrison L (2002) Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 47(4):571\u2013577. https:\/\/doi.org\/10.1067\/mjd.2002.126257","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3_CR87","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00403-004-0465-4","volume":"296","author":"LI Harrison","year":"2004","unstructured":"Harrison LI, Skinner SL, Marbury TC, Owens ML, Kurup S, McKane S et al (2004) Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 296(1):6\u201311. https:\/\/doi.org\/10.1007\/s00403-004-0465-4","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"3_CR88","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","volume":"50","author":"M Lebwohl","year":"2004","unstructured":"Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J et al (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50(5):714\u2013721. https:\/\/doi.org\/10.1016\/j.jaad.2003.12.010","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3_CR89","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","volume":"140","author":"E Stockfleth","year":"2004","unstructured":"Stockfleth E, Christophers E, Benninghoff B, Sterry W (2004) Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 140(12):1542. https:\/\/doi.org\/10.1001\/archderm.140.12.1542-a","journal-title":"Arch Dermatol"},{"issue":"4","key":"3_CR90","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","volume":"51","author":"RM Szeimies","year":"2004","unstructured":"Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J et al (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 51(4):547\u2013555. https:\/\/doi.org\/10.1016\/j.jaad.2004.02.022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3_CR91","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.141.4.467","volume":"141","author":"N Korman","year":"2005","unstructured":"Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S et al (2005) Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141(4):467\u2013473. https:\/\/doi.org\/10.1001\/archderm.141.4.467","journal-title":"Arch Dermatol"},{"issue":"6","key":"3_CR92","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0190-9622(99)70261-6","volume":"41","author":"KR Beutner","year":"1999","unstructured":"Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41(6):1002\u20131007. https:\/\/doi.org\/10.1016\/s0190-9622(99)70261-6","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3_CR93","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1067\/mjd.2001.113689","volume":"44","author":"R Marks","year":"2001","unstructured":"Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL et al (2001) Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44(5):807\u2013813. https:\/\/doi.org\/10.1067\/mjd.2001.113689","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3_CR94","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","volume":"138","author":"S Shumack","year":"2002","unstructured":"Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A et al (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138(9):1165\u20131171. https:\/\/doi.org\/10.1001\/archderm.138.9.1165","journal-title":"Arch Dermatol"},{"issue":"6","key":"3_CR95","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","volume":"147","author":"W Sterry","year":"2002","unstructured":"Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K et al (2002) Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 147(6):1227\u20131236. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.05069.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"3_CR96","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","volume":"50","author":"J Geisse","year":"2004","unstructured":"Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722\u2013733. https:\/\/doi.org\/10.1016\/j.jaad.2003.11.066","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3_CR97","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1524-4725.2004.30116.x","volume":"30","author":"A Huber","year":"2004","unstructured":"Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, Haque R, Amonette RA (2004) Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 30(3):429\u2013430. https:\/\/doi.org\/10.1111\/j.1524-4725.2004.30116.x","journal-title":"Dermatol Surg"},{"issue":"10","key":"3_CR98","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/archderm.140.10.1284-b","volume":"140","author":"R Marks","year":"2004","unstructured":"Marks R, Owens M, Walters SA (2004) Australian multi-centre trial G. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Arch Dermatol 140(10):1284\u20131285. https:\/\/doi.org\/10.1001\/archderm.140.10.1284-b","journal-title":"Arch Dermatol"},{"issue":"3","key":"3_CR99","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2230.2004.01456.x","volume":"29","author":"D Vidal","year":"2004","unstructured":"Vidal D, Alomar A (2004) Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol 29(3):237\u2013239. https:\/\/doi.org\/10.1111\/j.1365-2230.2004.01456.x","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"3_CR100","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2230.2004.01601.x","volume":"29","author":"D Vidal","year":"2004","unstructured":"Vidal D, Matias-Guiu X, Alomar A (2004) Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 29(5):518\u2013525. https:\/\/doi.org\/10.1111\/j.1365-2230.2004.01601.x","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"3_CR101","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jamaoncol.2018.1888","volume":"4","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P et al (2018) Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial. JAMA Oncol 4(11):1583\u20131588. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1888","journal-title":"JAMA Oncol"},{"issue":"1","key":"3_CR102","doi-asserted-by":"publisher","first-page":"1796002","DOI":"10.1080\/2162402X.2020.1796002","volume":"9","author":"G Frega","year":"2020","unstructured":"Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G et al (2020) Trial watch: experimental TLR7\/TLR8 agonists for oncological indications. Oncoimmunology. 9(1):1796002. https:\/\/doi.org\/10.1080\/2162402X.2020.1796002","journal-title":"Oncoimmunology."},{"issue":"8","key":"3_CR103","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1471-4906(02)02259-7","volume":"23","author":"M Rehli","year":"2002","unstructured":"Rehli M (2002) Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23(8):375\u2013378. https:\/\/doi.org\/10.1016\/s1471-4906(02)02259-7","journal-title":"Trends Immunol"},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.2147\/OTT.S247050","volume":"13","author":"L Karapetyan","year":"2020","unstructured":"Karapetyan L, Luke JJ, Davar D (2020) Toll-like receptor 9 agonists in cancer. Onco Targets Ther 13:10039\u201310060. https:\/\/doi.org\/10.2147\/OTT.S247050","journal-title":"Onco Targets Ther"},{"issue":"10","key":"3_CR105","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/annonc\/mdy326","volume":"29","author":"M Thomas","year":"2018","unstructured":"Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E et al (2018) Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol 29(10):2076\u20132084. https:\/\/doi.org\/10.1093\/annonc\/mdy326","journal-title":"Ann Oncol"},{"issue":"9","key":"3_CR106","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00432-014-1682-7","volume":"140","author":"HJ Schmoll","year":"2014","unstructured":"Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H et al (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 140(9):1615\u20131624. https:\/\/doi.org\/10.1007\/s00432-014-1682-7","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"3_CR107","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","volume":"8","author":"MJ Frank","year":"2018","unstructured":"Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK et al (2018) In Situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov 8(10):1258\u20131269. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0743","journal-title":"Cancer Discov"},{"issue":"10","key":"3_CR108","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ et al (2018) SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib. Multicenter Study. Cancer Discov. 8(10):1250\u20131257. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0280","journal-title":"Multicenter Study. Cancer Discov."},{"issue":"15","key":"3_CR109","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1200\/JCO.2021.39.15_suppl.508","volume":"39","author":"AJ Chien","year":"2021","unstructured":"Chien AJ, Soliman HH, Ewing CA, Boughey JC, Campbell MJ, Rugo HS et al (2021) Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II\/III breast cancer: Results from the I-SPY 2 trial. J Clin Oncol 39(15):508. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.508","journal-title":"J Clin Oncol"},{"issue":"5","key":"3_CR110","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.4049\/jimmunol.1900742","volume":"204","author":"CD Lemke-Miltner","year":"2020","unstructured":"Lemke-Miltner CD, Blackwell SE, Yin C, Krug AE, Morris AJ, Krieg AM et al (2020) Antibody opsonization of a TLR9 agonist-containing virus-like particle enhances In Situ immunization. J Immunol 204(5):1386\u20131394. https:\/\/doi.org\/10.4049\/jimmunol.1900742","journal-title":"J Immunol"},{"key":"3_CR111","doi-asserted-by":"publisher","unstructured":"Sabree SA, Voigt AP, Blackwell SE, Vishwakarma A, Chimenti MS, Salem AK, et al (2021) Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J Immunother Cancer 9(6). https:\/\/doi.org\/10.1136\/jitc-2021-002484","DOI":"10.1136\/jitc-2021-002484"},{"issue":"Suppl 1","key":"3_CR112","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1136\/LBA2019.4","volume":"8","author":"M Milhem","year":"2020","unstructured":"Milhem M, Zakharia Y, Davar D, Buchbinder E, Medina T, Daud A et al (2020) O85 durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. J Immunother Cancer 8(Suppl 1):A2. https:\/\/doi.org\/10.1136\/LBA2019.4","journal-title":"J Immunother Cancer"},{"key":"3_CR113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0425","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D et al (2021) Overcoming PD-1 blockade resistance with CpG-A Toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0425","journal-title":"Cancer Discov"},{"issue":"1","key":"3_CR114","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41467-021-22088-1","volume":"12","author":"MC Brown","year":"2021","unstructured":"Brown MC, Mosaheb MM, Mohme M, McKay ZP, Holl EK, Kastan JP et al (2021) Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat Commun 12(1):1858. https:\/\/doi.org\/10.1038\/s41467-021-22088-1","journal-title":"Nat Commun"},{"key":"3_CR115","doi-asserted-by":"publisher","unstructured":"Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, et al (2017) Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9(408). https:\/\/doi.org\/10.1126\/scitranslmed.aan4220","DOI":"10.1126\/scitranslmed.aan4220"},{"issue":"8","key":"3_CR116","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/0008-5472.CAN-15-2142","volume":"76","author":"X Yu","year":"2016","unstructured":"Yu X, Wang H, Li X, Guo C, Yuan F, Fisher PB et al (2016) Activation of the MDA-5-IPS-1 viral sensing pathway induces cancer cell death and Type I IFN-dependent antitumor immunity. Cancer Res 76(8):2166\u20132176. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2142","journal-title":"Cancer Res"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.virol.2015.09.023","volume":"487","author":"I Akhrymuk","year":"2016","unstructured":"Akhrymuk I, Frolov I, Frolova EI (2016) Both RIG-I and MDA5 detect alphavirus replication in concentration-dependent mode. Virology 487:230\u2013241. https:\/\/doi.org\/10.1016\/j.virol.2015.09.023","journal-title":"Virology"},{"issue":"2","key":"3_CR118","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ymthe.2020.11.002","volume":"29","author":"FL Komdeur","year":"2021","unstructured":"Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN et al (2021) First-in-human Phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol Ther 29(2):611\u2013625. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.002","journal-title":"Mol Ther"},{"key":"3_CR119","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-523458\/v1","author":"K Edward","year":"2021","unstructured":"Edward K, Agnieszka D, Jacqueline H, Lingxin K, De Ana A, Jeffrey B et al (2021). Nature Portfolio. https:\/\/doi.org\/10.21203\/rs.3.rs-523458\/v1","journal-title":"Nature Portfolio"},{"issue":"4","key":"3_CR120","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrg3199","volume":"13","author":"C Feschotte","year":"2012","unstructured":"Feschotte C, Gilbert C (2012) Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet 13(4):283\u2013296. https:\/\/doi.org\/10.1038\/nrg3199","journal-title":"Nat Rev Genet"},{"issue":"1","key":"3_CR121","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1172\/JCI69739","volume":"124","author":"SC Navada","year":"2014","unstructured":"Navada SC, Steinmann J, Lubbert M, Silverman LR (2014) Clinical development of demethylating agents in hematology. J Clin Invest 124(1):40\u201346. https:\/\/doi.org\/10.1172\/JCI69739","journal-title":"J Clin Invest"},{"issue":"5","key":"3_CR122","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961\u2013973. https:\/\/doi.org\/10.1016\/j.cell.2015.07.056","journal-title":"Cell"},{"issue":"5","key":"3_CR123","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974\u2013986. https:\/\/doi.org\/10.1016\/j.cell.2015.07.011","journal-title":"Cell"},{"issue":"2","key":"3_CR124","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/1078-0432.CCR-14-0388","volume":"21","author":"K Rycaj","year":"2015","unstructured":"Rycaj K, Plummer JB, Yin B, Li M, Garza J, Radvanyi L et al (2015) Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin Cancer Res 21(2):471\u2013483. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0388","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3_CR125","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jnci\/djr540","volume":"104","author":"F Wang-Johanning","year":"2012","unstructured":"Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K et al (2012) Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 104(3):189\u2013210. https:\/\/doi.org\/10.1093\/jnci\/djr540","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"3_CR126","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-14-3197","volume":"21","author":"J Krishnamurthy","year":"2015","unstructured":"Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN et al (2015) Genetic engineering of T cells to target HERV-K, an ancient retrovirus on melanoma. Clin Cancer Res 21(14):3241\u20133251. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3197","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3_CR127","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","volume":"4","author":"J Wrangle","year":"2013","unstructured":"Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F et al (2013) Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4(11):2067\u20132079. https:\/\/doi.org\/10.18632\/oncotarget.1542","journal-title":"Oncotarget"},{"key":"3_CR128","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2017.01.004","volume":"54","author":"JF Linnekamp","year":"2017","unstructured":"Linnekamp JF, Butter R, Spijker R, Medema JP, van Laarhoven HWM (2017) Clinical and biological effects of demethylating agents on solid tumours\u2014a systematic review. Cancer Treat Rev 54:10\u201323. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.004","journal-title":"Cancer Treat Rev"},{"key":"3_CR129","doi-asserted-by":"publisher","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.016","volume":"29","author":"MR Middleton","year":"2018","unstructured":"Middleton MR, Wermke M, Calvo E, Chartash E, Zhou H, Zhao X et al (2018) LBA16\u2014Phase I\/II, multicenter, open-label study of intratumoral\/intralesional administration of the retinoic acid\u2013inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors. Ann Oncol 29:viii712. https:\/\/doi.org\/10.1093\/annonc\/mdy424.016","journal-title":"Ann Oncol"},{"issue":"24","key":"3_CR130","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.18632\/oncotarget.26729","volume":"10","author":"DL Elion","year":"2019","unstructured":"Elion DL, Cook RS (2019) Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor. Oncotarget 10(24):2338\u20132339. https:\/\/doi.org\/10.18632\/oncotarget.26729","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"3_CR131","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2020.38.15_suppl.3096","volume":"38","author":"T Eigentler","year":"2020","unstructured":"Eigentler T, Bauernfeind FG, Becker JC, Brossart P, Fluck M, Heinzerling L et al (2020) A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. J Clin Oncol 38(15_suppl):3096. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3096","journal-title":"J Clin Oncol"},{"issue":"7","key":"3_CR132","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/cgt.2017.15","volume":"24","author":"K Fujita","year":"2017","unstructured":"Fujita K, Nakai Y, Kawashima A, Ujike T, Nagahara A, Nakajima T et al (2017) Phase I\/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. Cancer Gene Ther 24(7):277\u2013281. https:\/\/doi.org\/10.1038\/cgt.2017.15","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"3_CR133","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/cas.14366","volume":"111","author":"K Fujita","year":"2020","unstructured":"Fujita K, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M et al (2020) Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. Cancer Sci 111(5):1692\u20131698. https:\/\/doi.org\/10.1111\/cas.14366","journal-title":"Cancer Sci"},{"issue":"11","key":"3_CR134","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3390\/cancers12113158","volume":"12","author":"S Iurescia","year":"2020","unstructured":"Iurescia S, Fioretti D, Rinaldi M (2020) The innate immune signalling pathways: turning RIG-I sensor activation against cancer. Cancers (Basel) 12(11):3158. https:\/\/doi.org\/10.3390\/cancers12113158","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3_CR135","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1084\/jem.20061845","volume":"204","author":"ZJ Roberts","year":"2007","unstructured":"Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T et al (2007) The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204(7):1559\u20131569. https:\/\/doi.org\/10.1084\/jem.20061845","journal-title":"J Exp Med"},{"issue":"47","key":"3_CR136","doi-asserted-by":"publisher","first-page":"39776","DOI":"10.1074\/jbc.M112.382986","volume":"287","author":"D Prantner","year":"2012","unstructured":"Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA et al (2012) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem 287(47):39776\u201339788. https:\/\/doi.org\/10.1074\/jbc.M112.382986","journal-title":"J Biol Chem"},{"issue":"1","key":"3_CR137","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G (2020) Trial watch: STING agonists in cancer therapy. Oncoimmunology 9(1):1777624. https:\/\/doi.org\/10.1080\/2162402X.2020.1777624","journal-title":"Oncoimmunology"},{"issue":"10","key":"3_CR138","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","volume":"190","author":"J Conlon","year":"2013","unstructured":"Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z et al (2013) Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 190(10):5216\u20135225. https:\/\/doi.org\/10.4049\/jimmunol.1300097","journal-title":"J Immunol"},{"key":"3_CR139","doi-asserted-by":"publisher","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","volume":"29","author":"KJ Harrington","year":"2018","unstructured":"Harrington KJ, Brody J, Ingham M, Strauss J, Cemerski S, Wang M et al (2018) LBA15\u2014preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol 29:viii712. https:\/\/doi.org\/10.1093\/annonc\/mdy424.015","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"3_CR140","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1200\/JCO.2019.37.15_suppl.2507","volume":"37","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Sandhu SK, Hamid O, Spreafico A, Kasper S, Dummer R et al (2019) Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced\/metastatic solid tumors or lymphomas. J Clin Oncol 37(15_suppl):2507. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2507","journal-title":"J Clin Oncol"},{"issue":"6506","key":"3_CR141","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1126\/science.abb4255","volume":"369","author":"EN Chin","year":"2020","unstructured":"Chin EN, Yu C, Vartabedian VF, Jia Y, Kumar M, Gamo AM et al (2020) Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369(6506):993\u2013999. https:\/\/doi.org\/10.1126\/science.abb4255","journal-title":"Science"},{"issue":"6506","key":"3_CR142","doi-asserted-by":"publisher","first-page":"aba6098","DOI":"10.1126\/science.aba6098","volume":"369","author":"BS Pan","year":"2020","unstructured":"Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN et al (2020) An orally available non-nucleotide STING agonist with antitumor activity. Science 369(6506):aba6098. https:\/\/doi.org\/10.1126\/science.aba6098","journal-title":"Science"},{"key":"3_CR143","doi-asserted-by":"publisher","unstructured":"Ager CR, Boda A, Rajapakshe K, Lea ST, Di Francesco ME, Jayaprakash P, et al (2021) High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer 9(8). https:\/\/doi.org\/10.1136\/jitc-2021-003246","DOI":"10.1136\/jitc-2021-003246"},{"issue":"8","key":"3_CR144","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","volume":"5","author":"CR Ager","year":"2017","unstructured":"Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, Curran MA (2017) Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res 5(8):676\u2013684. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0049","journal-title":"Cancer Immunol Res"},{"key":"3_CR145","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coviro.2020.07.012","volume":"44","author":"MM Mosaheb","year":"2020","unstructured":"Mosaheb MM, Brown MC, Dobrikova EY, Dobrikov MI, Gromeier M (2020) Harnessing virus tropism for dendritic cells for vaccine design. Curr Opin Virol 44:73\u201380. https:\/\/doi.org\/10.1016\/j.coviro.2020.07.012","journal-title":"Curr Opin Virol"},{"issue":"8","key":"3_CR146","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00251-002-0493-1","volume":"54","author":"MT Vossen","year":"2002","unstructured":"Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ (2002) Viral immune evasion: a masterpiece of evolution. Immunogenetics 54(8):527\u2013542. https:\/\/doi.org\/10.1007\/s00251-002-0493-1","journal-title":"Immunogenetics"},{"key":"3_CR147","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev.cellbio.15.1.579","volume":"15","author":"JW Yewdell","year":"1999","unstructured":"Yewdell JW, Bennink JR (1999) Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu Rev Cell Dev Biol 15:579\u2013606. https:\/\/doi.org\/10.1146\/annurev.cellbio.15.1.579","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"12","key":"3_CR148","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nri2436","volume":"8","author":"AG Bowie","year":"2008","unstructured":"Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8(12):911\u2013922. https:\/\/doi.org\/10.1038\/nri2436","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"3_CR149","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nrc1750","volume":"5","author":"KA Parato","year":"2005","unstructured":"Parato KA, Senger D, Forsyth PA, Bell JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5(12):965\u2013976. https:\/\/doi.org\/10.1038\/nrc1750","journal-title":"Nat Rev Cancer"},{"issue":"226","key":"3_CR150","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P et al (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32. https:\/\/doi.org\/10.1126\/scitranslmed.3008095","journal-title":"Sci Transl Med"},{"issue":"1","key":"3_CR151","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","volume":"23","author":"X Li","year":"2017","unstructured":"Li X, Wang P, Li H, Du X, Liu M, Huang Q et al (2017) The efficacy of oncolytic adenovirus is mediated by t-cell responses against virus and tumor in Syrian Hamster model. Clin Cancer Res 23(1):239\u2013249. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0477","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3_CR152","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642\u2013662. https:\/\/doi.org\/10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3_CR153","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nri2937","volume":"11","author":"SR Paludan","year":"2011","unstructured":"Paludan SR, Bowie AG, Horan KA, Fitzgerald KA (2011) Recognition of herpesviruses by the innate immune system. Nat Rev Immunol 11(2):143\u2013154. https:\/\/doi.org\/10.1038\/nri2937","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"3_CR154","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"issue":"13","key":"3_CR155","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA et al (2016) Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann Surg Oncol 23(13):4169\u20134177. https:\/\/doi.org\/10.1245\/s10434-016-5286-0","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"3_CR156","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.3390\/cancers12123514","volume":"12","author":"MS Koch","year":"2020","unstructured":"Koch MS, Lawler SE, Chiocca EA (2020) HSV-1 oncolytic viruses from bench to bedside: an overview of current clinical trials. Cancers (Basel) 12(12):3514. https:\/\/doi.org\/10.3390\/cancers12123514","journal-title":"Cancers (Basel)"},{"key":"3_CR157","doi-asserted-by":"publisher","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(6):1109\u20131119 e10. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"3_CR158","doi-asserted-by":"publisher","unstructured":"Najjar YG (2021) Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer 9(7). https:\/\/doi.org\/10.1136\/jitc-2021-002820","DOI":"10.1136\/jitc-2021-002820"},{"key":"3_CR159","doi-asserted-by":"publisher","unstructured":"Todo T (2019) ATIM-14. Results of phase II clinical trial of oncolytic herpes virus G47\u0394 in patients with glioblastoma. Neuro-Oncology 21(Supplement_6):vi4-vi. https:\/\/doi.org\/10.1093\/neuonc\/noz175.014","DOI":"10.1093\/neuonc\/noz175.014"},{"key":"3_CR160","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","volume":"17","author":"EA Chiocca","year":"2020","unstructured":"Chiocca EA, Nakashima H, Kasai K, Fernandez SA, Oglesbee M (2020) Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene. Mol Ther Meth Clin Dev 17:871\u2013893. https:\/\/doi.org\/10.1016\/j.omtm.2020.03.028","journal-title":"Mol Ther Meth Clin Dev"},{"issue":"1","key":"3_CR161","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","volume":"7","author":"S Thomas","year":"2019","unstructured":"Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK et al (2019) Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer 7(1):214. https:\/\/doi.org\/10.1186\/s40425-019-0682-1","journal-title":"J Immunother Cancer"},{"key":"3_CR162","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.omto.2020.08.004","volume":"18","author":"EM Kennedy","year":"2020","unstructured":"Kennedy EM, Farkaly T, Grzesik P, Lee J, Denslow A, Hewett J et al (2020) Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability. Mol Ther Oncolytics 18:476\u2013490. https:\/\/doi.org\/10.1016\/j.omto.2020.08.004","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"3_CR163","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/humc.2016.031","volume":"27","author":"DM Patel","year":"2016","unstructured":"Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM (2016) Design of a Phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent\/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum Gene Ther Clin Dev 27(2):69\u201378. https:\/\/doi.org\/10.1089\/humc.2016.031","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"3","key":"3_CR164","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/2326-6066.CIR-20-0609","volume":"9","author":"BB Haines","year":"2021","unstructured":"Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J et al (2021) ONCR-177, an oncolytic HSV-1 designed to potently activate systemic antitumor immunity. Cancer Immunol Res 9(3):291\u2013308. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0609","journal-title":"Cancer Immunol Res"},{"issue":"13 Supplement","key":"3_CR165","doi-asserted-by":"publisher","first-page":"LB180","DOI":"10.1158\/1538-7445.AM2021-LB180","volume":"81","author":"KJ Harrington","year":"2021","unstructured":"Harrington KJ, Aroldi F, Sacco JJ, Milhem MM, Curti BD, Vanderwalde AM et al (2021) Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation. Cancer Res 81(13 Supplement):LB180. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-LB180","journal-title":"Cancer Res"},{"issue":"13 Supplement","key":"3_CR166","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1158\/1538-7445.AM2021-2597","volume":"81","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Yan R, Tang Y, Zhan B, Huang Y, Ni D et al (2021) Abstract 2597: non-clinical studies of systemic delivery of oncolytic virus arms with IL-12 and anti-PD-1 antibody. Can Res 81(13 Supplement):2597. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-2597","journal-title":"Can Res"},{"issue":"7","key":"3_CR167","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/JVI.02192-06","volume":"81","author":"J Zhu","year":"2007","unstructured":"Zhu J, Huang X, Yang Y (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81(7):3170\u20133180. https:\/\/doi.org\/10.1128\/JVI.02192-06","journal-title":"J Virol"},{"issue":"13","key":"3_CR168","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1128\/JVI.00500-16","volume":"90","author":"D Anghelina","year":"2016","unstructured":"Anghelina D, Lam E, Falck-Pedersen E (2016) Diminished innate antiviral response to adenovirus vectors in cGAS\/STING-deficient mice minimally impacts adaptive immunity. J Virol 90(13):5915\u20135927. https:\/\/doi.org\/10.1128\/JVI.00500-16","journal-title":"J Virol"},{"issue":"5","key":"3_CR169","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ni.3433","volume":"17","author":"F Wang","year":"2016","unstructured":"Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ et al (2016) S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. Nat Immunol 17(5):514\u2013522. https:\/\/doi.org\/10.1038\/ni.3433","journal-title":"Nat Immunol"},{"issue":"9","key":"3_CR170","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1089\/hum.2011.002","volume":"22","author":"M Suzuki","year":"2011","unstructured":"Suzuki M, Cela R, Bertin TK, Sule G, Cerullo V, Rodgers JR et al (2011) NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Hum Gene Ther 22(9):1071\u20131082. https:\/\/doi.org\/10.1089\/hum.2011.002","journal-title":"Hum Gene Ther"},{"issue":"7183","key":"3_CR171","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature06664","volume":"452","author":"DA Muruve","year":"2008","unstructured":"Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ et al (2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452(7183):103\u2013107. https:\/\/doi.org\/10.1038\/nature06664","journal-title":"Nature"},{"issue":"24","key":"3_CR172","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1002\/1873-3468.13696","volume":"593","author":"S Atasheva","year":"2019","unstructured":"Atasheva S, Yao J, Shayakhmetov DM (2019) Innate immunity to adenovirus: lessons from mice. FEBS Lett 593(24):3461\u20133483. https:\/\/doi.org\/10.1002\/1873-3468.13696","journal-title":"FEBS Lett"},{"key":"3_CR173","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fonc.2019.00564","volume":"9","author":"S Di Somma","year":"2019","unstructured":"Di Somma S, Iannuzzi CA, Passaro C, Forte IM, Iannone R, Gigantino V et al (2019) The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth. Front Oncol 9:564. https:\/\/doi.org\/10.3389\/fonc.2019.00564","journal-title":"Front Oncol"},{"issue":"6","key":"3_CR174","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/mt.2013.51","volume":"21","author":"I Liikanen","year":"2013","unstructured":"Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P et al (2013) Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 21(6):1212\u20131223. https:\/\/doi.org\/10.1038\/mt.2013.51","journal-title":"Mol Ther"},{"issue":"1","key":"3_CR175","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","volume":"11","author":"J Ma","year":"2020","unstructured":"Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D et al (2020) Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis 11(1):48. https:\/\/doi.org\/10.1038\/s41419-020-2236-3","journal-title":"Cell Death Dis"},{"issue":"5","key":"3_CR176","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","volume":"98","author":"K Garber","year":"2006","unstructured":"Garber K (2006) China approves world\u2019s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98(5):298\u2013300. https:\/\/doi.org\/10.1093\/jnci\/djj111","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"3_CR177","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS et al (2018) Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36(14):1419\u20131427. https:\/\/doi.org\/10.1200\/JCO.2017.75.8219","journal-title":"J Clin Oncol"},{"key":"3_CR178","doi-asserted-by":"publisher","unstructured":"Zadeh G, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, et al (2020) LTBK-04. phase 2 multicenter study of the oncolytic adenovirus DNX-2401 (TASADENOTUREV) in combination with pembrolizumab for recurrent glioblastoma; captive study (KEYNOTE-192). Neuro-Oncology. 22(Supplement_2):ii237-ii. https:\/\/doi.org\/10.1093\/neuonc\/noaa215.989","DOI":"10.1093\/neuonc\/noaa215.989"},{"issue":"15_suppl","key":"3_CR179","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1200\/jco.2012.30.15_suppl.4593","volume":"30","author":"TW Friedlander","year":"2012","unstructured":"Friedlander TW, Weinberg VK, Yeung A, Burke J, Lamm DL, McKiernan JM et al (2012) Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: updated results of a phase I\/II trial. J Clin Oncol 30(15_suppl):4593. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.4593","journal-title":"J Clin Oncol"},{"issue":"4","key":"3_CR180","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/01.JU.0000556225.57786.36","volume":"201","author":"T Packiam Vignesh","year":"2019","unstructured":"Packiam Vignesh T, Barocas Daniel A, Chamie K, Davis Ronald L, Karim Kader A, Lamm Donald L et al (2019) MP43\u201302 CG0070, an oncolytic adenovirus, for bcg-unresponsive non-muscle-invasive bladder cancer (NMIBC): 18 month follow-up from a multicenter phase II trial. J Urol 201(4):617. https:\/\/doi.org\/10.1097\/01.JU.0000556225.57786.36","journal-title":"J Urol"},{"key":"3_CR181","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T et al (2016) Phase I study with ONCOS-102 for the treatment of solid tumors\u2014an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer 4:17. https:\/\/doi.org\/10.1186\/s40425-016-0121-5","journal-title":"J Immunother Cancer"},{"issue":"4_suppl","key":"3_CR182","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.2020.38.4_suppl.716","volume":"38","author":"BL Musher","year":"2020","unstructured":"Musher BL, Smaglo BG, Abidi W, Othman M, Patel K, Jing J et al (2020) A phase I\/II study combining a TMZ-CD40L\/4\u20131BBL-armed oncolytic adenovirus and nab-paclitaxel\/gemcitabine chemotherapy in advanced pancreatic cancer: an interim report. J Clin Oncol 38(4_suppl):716. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.716","journal-title":"J Clin Oncol"},{"key":"3_CR183","doi-asserted-by":"publisher","first-page":"v271","DOI":"10.1093\/annonc\/mdz247.037","volume":"30","author":"R Garcia-Carbonero","year":"2019","unstructured":"Garcia-Carbonero R, Gil Mart\u00edn M, Alvarez Gallego R, Macarulla Mercade T, Riesco Martinez MC, Guillen-Ponce C et al (2019) Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial. Ann Oncol 30:v271\u2013v272. https:\/\/doi.org\/10.1093\/annonc\/mdz247.037","journal-title":"Ann Oncol"},{"key":"3_CR184","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","volume":"20","author":"KN Barton","year":"2021","unstructured":"Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I et al (2021) Phase I trial of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy for the treatment of metastatic pancreatic cancer. Mol Ther Oncolytics 20:94\u2013104. https:\/\/doi.org\/10.1016\/j.omto.2020.11.006","journal-title":"Mol Ther Oncolytics"},{"issue":"14","key":"3_CR185","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","volume":"77","author":"H Jiang","year":"2017","unstructured":"Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM et al (2017) Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res 77(14):3894\u20133907. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0468","journal-title":"Cancer Res"},{"issue":"13 Supplement","key":"3_CR186","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1158\/1538-7445.AM2019-5013","volume":"79","author":"BR Champion","year":"2019","unstructured":"Champion BR, Besneux M, Patsalidou M, Silva A, Zonca M, Marino N et al (2019) Abstract 5013: NG-641: an oncolytic T-SIGn virus targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas. Can Res 79(13 Supplement):5013. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-5013","journal-title":"Can Res"},{"issue":"11","key":"3_CR187","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/cancers12113354","volume":"12","author":"M Peter","year":"2020","unstructured":"Peter M, Kuhnel F (2020) Oncolytic adenovirus in cancer immunotherapy. Cancers (Basel) 12(11):3354. https:\/\/doi.org\/10.3390\/cancers12113354","journal-title":"Cancers (Basel)"},{"key":"3_CR188","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.immunol.21.120601.141049","volume":"21","author":"BT Seet","year":"2003","unstructured":"Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C et al (2003) Poxviruses and immune evasion. Annu Rev Immunol 21:377\u2013423. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141049","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"3_CR189","doi-asserted-by":"publisher","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","volume":"5","author":"J Delaloye","year":"2009","unstructured":"Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S et al (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5(6):e1000480. https:\/\/doi.org\/10.1371\/journal.ppat.1000480","journal-title":"PLoS Pathog"},{"issue":"5","key":"3_CR190","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/ni1059","volume":"5","author":"Y Yang","year":"2004","unstructured":"Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5(5):508\u2013515. https:\/\/doi.org\/10.1038\/ni1059","journal-title":"Nat Immunol"},{"issue":"11","key":"3_CR191","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/sciimmunol.aal1713","volume":"2","author":"P Dai","year":"2017","unstructured":"Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D et al (2017) Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol. 2(11):1713. https:\/\/doi.org\/10.1126\/sciimmunol.aal1713","journal-title":"Sci Immunol."},{"issue":"3","key":"3_CR192","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M et al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19(3):329\u2013336. https:\/\/doi.org\/10.1038\/nm.3089","journal-title":"Nat Med"},{"issue":"8","key":"3_CR193","doi-asserted-by":"publisher","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","volume":"8","author":"M Moehler","year":"2019","unstructured":"Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW et al (2019) Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 8(8):1615817. https:\/\/doi.org\/10.1080\/2162402X.2019.1615817","journal-title":"Oncoimmunology."},{"key":"3_CR194","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0959-8049(20)31231-4","volume":"138","author":"C Monge","year":"2020","unstructured":"Monge C, Xie C, Brar G, Akoth E, Webb S, Mabry D et al (2020) A phase I\/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer. Eur J Cancer 138:S57\u2013S58. https:\/\/doi.org\/10.1016\/S0959-8049(20)31231-4","journal-title":"Eur J Cancer"},{"issue":"6","key":"3_CR195","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14712598.2019.1600669","volume":"19","author":"LE Torres-Dominguez","year":"2019","unstructured":"Torres-Dominguez LE, McFadden G (2019) Poxvirus oncolytic virotherapy. Expert Opin Biol Ther 19(6):561\u2013573. https:\/\/doi.org\/10.1080\/14712598.2019.1600669","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"3_CR196","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","volume":"23","author":"LK Mell","year":"2017","unstructured":"Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME et al (2017) Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res 23(19):5696\u20135702. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3232","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3_CR197","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/mt.2016.101","volume":"24","author":"S Downs-Canner","year":"2016","unstructured":"Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O\u2019Malley ME, Jones HL et al (2016) Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther 24(8):1492\u20131501. https:\/\/doi.org\/10.1038\/mt.2016.101","journal-title":"Mol Ther"},{"issue":"12","key":"3_CR198","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1073\/pnas.97.12.6803","volume":"97","author":"M Gromeier","year":"2000","unstructured":"Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 97(12):6803\u20136808","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"3_CR199","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/cncr.28862","volume":"120","author":"MC Brown","year":"2014","unstructured":"Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK et al (2014) Oncolytic polio virotherapy of cancer. Cancer 120(21):3277\u20133286. https:\/\/doi.org\/10.1002\/cncr.28862","journal-title":"Cancer"},{"issue":"6","key":"3_CR200","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.4049\/jimmunol.2000792","volume":"206","author":"ZP McKay","year":"2021","unstructured":"McKay ZP, Brown MC, Gromeier M (2021) Aryl hydrocarbon receptor signaling controls CD155 expression on macrophages and mediates tumor immunosuppression. J Immunol 206(6):1385\u20131394. https:\/\/doi.org\/10.4049\/jimmunol.2000792","journal-title":"J Immunol"},{"issue":"1","key":"3_CR201","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41467-019-13939-z","volume":"11","author":"MM Mosaheb","year":"2020","unstructured":"Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H et al (2020) Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun 11(1):524. https:\/\/doi.org\/10.1038\/s41467-019-13939-z","journal-title":"Nat Commun"},{"issue":"2","key":"3_CR202","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379(2):150\u2013161. https:\/\/doi.org\/10.1056\/NEJMoa1716435","journal-title":"N Engl J Med"},{"key":"3_CR203","doi-asserted-by":"publisher","unstructured":"Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA, et al (2021) Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer. 9(4). https:\/\/doi.org\/10.1136\/jitc-2020-002203","DOI":"10.1136\/jitc-2020-002203"},{"issue":"13 Supplement","key":"3_CR204","doi-asserted-by":"publisher","first-page":"CT242","DOI":"10.1158\/1538-7445.AM2021-CT242","volume":"81","author":"BA Inman","year":"2021","unstructured":"Inman BA, Balar AV, Milowsky MI, Pruthi RS, Polasek MJ, Morris SR et al (2021) Abstract CT242: LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO in patients with advanced solid tumors. Cancer Res 81(13 Supplement):CT242. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-CT242","journal-title":"Cancer Res"},{"issue":"15","key":"3_CR205","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1200\/JCO.2021.39.15_suppl.2560","volume":"39","author":"L Neighbours","year":"2021","unstructured":"Neighbours L, McKay ZP, Gromeier M, Nichols G, Kelly AT, Corum D et al (2021) Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model. J Clin Oncol 39(15):2560. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2560","journal-title":"J Clin Oncol"},{"issue":"30","key":"3_CR206","doi-asserted-by":"publisher","first-page":"11099","DOI":"10.1073\/pnas.0404310101","volume":"101","author":"KL Norman","year":"2004","unstructured":"Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW (2004) Reovirus oncolysis: the Ras\/RalGEF\/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 101(30):11099\u201311104. https:\/\/doi.org\/10.1073\/pnas.0404310101","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3_CR207","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1172\/JCI9871","volume":"105","author":"KL Norman","year":"2000","unstructured":"Norman KL, Lee PW (2000) Reovirus as a novel oncolytic agent. J Clin Invest 105(8):1035\u20131038. https:\/\/doi.org\/10.1172\/JCI9871","journal-title":"J Clin Invest"},{"issue":"6","key":"3_CR208","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/v12060667","volume":"12","author":"AT Abad","year":"2020","unstructured":"Abad AT, Danthi P (2020) Recognition of reovirus RNAs by the innate immune system. Viruses 12(6):667. https:\/\/doi.org\/10.3390\/v12060667","journal-title":"Viruses"},{"issue":"13","key":"3_CR209","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","volume":"15","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T et al (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15(13):4374\u20134381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0334","journal-title":"Clin Cancer Res"},{"issue":"22","key":"3_CR210","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","volume":"14","author":"RJ Prestwich","year":"2008","unstructured":"Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T et al (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14(22):7358\u20137366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0831","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3_CR211","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10637-012-9865-z","volume":"31","author":"DG Morris","year":"2013","unstructured":"Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH et al (2013) REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs 31(3):696\u2013706. https:\/\/doi.org\/10.1007\/s10637-012-9865-z","journal-title":"Invest New Drugs"},{"issue":"4","key":"3_CR212","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","volume":"79","author":"D Mahalingam","year":"2017","unstructured":"Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R et al (2017) A phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol 79(4):697\u2013703. https:\/\/doi.org\/10.1007\/s00280-017-3260-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3_CR213","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-017-4538-4","volume":"167","author":"V Bernstein","year":"2018","unstructured":"Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK et al (2018) A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat 167(2):485\u201393. https:\/\/doi.org\/10.1007\/s10549-017-4538-4","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"3_CR214","doi-asserted-by":"publisher","first-page":"e20512","DOI":"10.1200\/JCO.2016.34.15_suppl.e20512","volume":"34","author":"D Morris","year":"2016","unstructured":"Morris D, Tu D, Tehfe MA, Nicholas GA, Goffin JR, Gregg RW et al (2016) A randomized phase II study of Reolysin in patients with previously treated advanced or metatstatic non small cell lung cancer (NSCLC) receiving standard salvage chemotherapy\u2014canadian cancer trials group IND 211. J Clin Oncol 34(15):e20512. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.e20512","journal-title":"J Clin Oncol"},{"issue":"11 Supplement","key":"3_CR215","doi-asserted-by":"publisher","first-page":"C22","DOI":"10.1158\/1535-7163.TARG-11-C22","volume":"10","author":"AB Karnad","year":"2011","unstructured":"Karnad AB, Haigentz M, Miley T, Coffey M, Gill G, Mita M (2011) Abstract C22: a phase II study of intravenous wild-type reovirus (Reolysin\u00ae) in combination with paclitaxel plus carboplatin in patients with platinum refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck. Mol Cancer Ther 10(11 Supplement):C22. https:\/\/doi.org\/10.1158\/1535-7163.TARG-11-C22","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3_CR216","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D et al (2016) Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther 24(6):1150\u20131158. https:\/\/doi.org\/10.1038\/mt.2016.66","journal-title":"Mol Ther"},{"issue":"422","key":"3_CR217","doi-asserted-by":"publisher","first-page":"aam7577","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"A Samson","year":"2018","unstructured":"Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ et al (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 10(422):aam7577. https:\/\/doi.org\/10.1126\/scitranslmed.aam7577","journal-title":"Sci Transl Med."},{"issue":"11","key":"3_CR218","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.3390\/cancers12113219","volume":"12","author":"L Muller","year":"2020","unstructured":"Muller L, Berkeley R, Barr T, Ilett E, Errington-Mais F (2020) Past, present and future of oncolytic reovirus. Cancers (Basel) 12(11):3219. https:\/\/doi.org\/10.3390\/cancers12113219","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3_CR219","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.celrep.2012.10.005","volume":"2","author":"Q Feng","year":"2012","unstructured":"Feng Q, Hato SV, Langereis MA, Zoll J, Virgen-Slane R, Peisley A et al (2012) MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. Cell Rep 2(5):1187\u20131196. https:\/\/doi.org\/10.1016\/j.celrep.2012.10.005","journal-title":"Cell Rep"},{"issue":"19","key":"3_CR220","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","volume":"25","author":"NE Annels","year":"2019","unstructured":"Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M et al (2019) Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 25(19):5818. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4022","journal-title":"Clin Cancer Res"},{"key":"3_CR221","doi-asserted-by":"publisher","unstructured":"Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, et al (2021) Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol. JCO2003246. https:\/\/doi.org\/10.1200\/JCO.20.03246","DOI":"10.1200\/JCO.20.03246"},{"issue":"13 Supplement","key":"3_CR222","doi-asserted-by":"publisher","first-page":"CT139","DOI":"10.1158\/1538-7445.AM2021-CT139","volume":"81","author":"AW Silk","year":"2021","unstructured":"Silk AW, Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C et al (2021) Abstract CT139: intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. Cancer Res 81(13 Supplement):CT139. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-CT139","journal-title":"Cancer Res"},{"issue":"4","key":"3_CR223","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4):263\u2013275. https:\/\/doi.org\/10.1016\/s1535-6108(03)00241-1","journal-title":"Cancer Cell"},{"issue":"7","key":"3_CR224","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ni1087","volume":"5","author":"M Yoneyama","year":"2004","unstructured":"Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M et al (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5(7):730\u2013737. https:\/\/doi.org\/10.1038\/ni1087","journal-title":"Nat Immunol"},{"issue":"15","key":"3_CR225","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1073\/pnas.0400937101","volume":"101","author":"JM Lund","year":"2004","unstructured":"Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW et al (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101(15):5598\u20135603. https:\/\/doi.org\/10.1073\/pnas.0400937101","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3_CR226","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.virol.2006.10.026","volume":"360","author":"JE Johnson","year":"2007","unstructured":"Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K et al (2007) Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360(1):36\u201349. https:\/\/doi.org\/10.1016\/j.virol.2006.10.026","journal-title":"Virology"},{"issue":"4","key":"3_CR227","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/hum.2009.111","volume":"21","author":"N Jenks","year":"2010","unstructured":"Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A et al (2010) Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 21(4):451\u2013462. https:\/\/doi.org\/10.1089\/hum.2009.111","journal-title":"Hum Gene Ther"},{"issue":"16","key":"3_CR228","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1128\/jvi.77.16.8843-8856.2003","volume":"77","author":"M Obuchi","year":"2003","unstructured":"Obuchi M, Fernandez M, Barber GN (2003) Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 77(16):8843\u20138856. https:\/\/doi.org\/10.1128\/jvi.77.16.8843-8856.2003","journal-title":"J Virol"},{"issue":"32","key":"3_CR229","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.18632\/oncotarget.5320","volume":"6","author":"MR Patel","year":"2015","unstructured":"Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K et al (2015) Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget 6(32):33165\u201333177. https:\/\/doi.org\/10.18632\/oncotarget.5320","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"3_CR230","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.2021.39.15_suppl.2500","volume":"39","author":"J Cook","year":"2021","unstructured":"Cook J, Peng KW, Geyer SM, Ginos BF, Dueck AC, Packiriswamy N et al (2021) Clinical activity of systemic VSV-IFN\u03b2-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma. J Clin Oncol 39(15_suppl):2500. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2500","journal-title":"J Clin Oncol"},{"issue":"7715","key":"3_CR231","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0140-6736(71)92086-1","volume":"2","author":"AZ Bluming","year":"1971","unstructured":"Bluming AZ, Ziegler JL (1971) Regression of Burkitt\u2019s lymphoma in association with measles infection. Lancet 2(7715):105\u2013106. https:\/\/doi.org\/10.1016\/s0140-6736(71)92086-1","journal-title":"Lancet"},{"issue":"4","key":"3_CR232","doi-asserted-by":"publisher","first-page":"e1004081","DOI":"10.1371\/journal.ppat.1004081","volume":"10","author":"S Runge","year":"2014","unstructured":"Runge S, Sparrer KM, Lassig C, Hembach K, Baum A, Garcia-Sastre A et al (2014) In vivo ligands of MDA5 and RIG-I in measles virus-infected cells. PLoS Pathog 10(4):e1004081. https:\/\/doi.org\/10.1371\/journal.ppat.1004081","journal-title":"PLoS Pathog"},{"issue":"1","key":"3_CR233","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.chom.2014.06.008","volume":"16","author":"AW Mesman","year":"2014","unstructured":"Mesman AW, Zijlstra-Willems EM, Kaptein TM, de Swart RL, Davis ME, Ludlow M et al (2014) Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatases. Cell Host Microbe 16(1):31\u201342. https:\/\/doi.org\/10.1016\/j.chom.2014.06.008","journal-title":"Cell Host Microbe"},{"issue":"6465","key":"3_CR234","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aay6485","volume":"366","author":"MJ Mina","year":"2019","unstructured":"Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M et al (2019) Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 366(6465):599\u2013606. https:\/\/doi.org\/10.1126\/science.aay6485","journal-title":"Science"},{"issue":"7","key":"3_CR235","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","volume":"106","author":"L Heinzerling","year":"2005","unstructured":"Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R (2005) Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106(7):2287\u20132294. https:\/\/doi.org\/10.1182\/blood-2004-11-4558","journal-title":"Blood"},{"issue":"3","key":"3_CR236","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","volume":"70","author":"E Galanis","year":"2010","unstructured":"Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al (2010) Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70(3):875\u2013882. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2762","journal-title":"Cancer Res"},{"issue":"3","key":"3_CR237","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","volume":"13","author":"CE Engeland","year":"2021","unstructured":"Engeland CE, Ungerechts G (2021) Measles virus as an oncolytic immunotherapy. Cancers (Basel). 13(3):544. https:\/\/doi.org\/10.3390\/cancers13030544","journal-title":"Cancers (Basel)."},{"issue":"1","key":"3_CR238","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","volume":"75","author":"E Galanis","year":"2015","unstructured":"Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA et al (2015) Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 75(1):22\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2533","journal-title":"Cancer Res"},{"issue":"3","key":"3_CR239","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2010.01.020","volume":"140","author":"J Rehwinkel","year":"2010","unstructured":"Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K et al (2010) RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140(3):397\u2013408. https:\/\/doi.org\/10.1016\/j.cell.2010.01.020","journal-title":"Cell"},{"issue":"1","key":"3_CR240","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2005.04.010","volume":"23","author":"H Kato","year":"2005","unstructured":"Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K et al (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23(1):19\u201328. https:\/\/doi.org\/10.1016\/j.immuni.2005.04.010","journal-title":"Immunity"},{"issue":"12","key":"3_CR241","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/cancers12123552","volume":"12","author":"B Burman","year":"2020","unstructured":"Burman B, Pesci G, Zamarin D (2020) Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel) 12(12):3552. https:\/\/doi.org\/10.3390\/cancers12123552","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3_CR242","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF01741145","volume":"35","author":"P Schlag","year":"1992","unstructured":"Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C et al (1992) Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35(5):325\u2013330. https:\/\/doi.org\/10.1007\/BF01741145","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3_CR243","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","volume":"9","author":"W Liang","year":"2003","unstructured":"Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y et al (2003) Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 9(3):495\u2013498. https:\/\/doi.org\/10.3748\/wjg.v9.i3.495","journal-title":"World J Gastroenterol"},{"issue":"1\u20132","key":"3_CR244","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/b:neon.0000021735.85511.05","volume":"67","author":"LK Csatary","year":"2004","unstructured":"Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B et al (2004) MTH-68\/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67(1\u20132):83\u201393. https:\/\/doi.org\/10.1023\/b:neon.0000021735.85511.05","journal-title":"J Neurooncol"},{"issue":"1B","key":"3_CR245","first-page":"635","volume":"19","author":"LK Csatary","year":"1999","unstructured":"Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T (1999) Beneficial treatment of patients with advanced cancer using a newcastle disease virus vaccine (MTH-68\/H). Anticancer Res 19(1B):635\u2013638","journal-title":"Anticancer Res"},{"issue":"9","key":"3_CR246","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","volume":"20","author":"AL Pecora","year":"2002","unstructured":"Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20(9):2251\u20132266. https:\/\/doi.org\/10.1200\/JCO.2002.08.042","journal-title":"J Clin Oncol"},{"issue":"8","key":"3_CR247","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","volume":"12","author":"SA Laurie","year":"2006","unstructured":"Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O\u2019Neil JD et al (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12(8):2555\u20132562. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2038","journal-title":"Clin Cancer Res"},{"issue":"16 Supplement","key":"3_CR248","doi-asserted-by":"publisher","first-page":"CT244","DOI":"10.1158\/1538-7445.AM2020-CT244","volume":"80","author":"GK Dy","year":"2020","unstructured":"Dy GK, Davar D, Galanis E, Townsley D, Karanovic D, Schwaederle M et al (2020) Abstract CT244: a phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors. Cancer Res 80(16 Supplement):CT244. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-CT244","journal-title":"Cancer Res"},{"key":"3_CR249","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fmicb.2010.00149","volume":"1","author":"J Eitel","year":"2010","unstructured":"Eitel J, Suttorp N, Opitz B (2010) Innate immune recognition and inflammasome activation in listeria monocytogenes infection. Front Microbiol 1:149. https:\/\/doi.org\/10.3389\/fmicb.2010.00149","journal-title":"Front Microbiol"},{"key":"3_CR250","doi-asserted-by":"publisher","first-page":"642316","DOI":"10.3389\/fimmu.2021.642316","volume":"12","author":"M Oladejo","year":"2021","unstructured":"Oladejo M, Paterson Y, Wood LM (2021) Clinical experience and recent advances in the development of listeria-based tumor immunotherapies. Front Immunol 12:642316. https:\/\/doi.org\/10.3389\/fimmu.2021.642316","journal-title":"Front Immunol"},{"issue":"14","key":"3_CR251","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","volume":"26","author":"T Tsujikawa","year":"2020","unstructured":"Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B et al (2020) Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer. Clin Cancer Res 26(14):3578\u20133588. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3978","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3_CR252","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","volume":"28","author":"P Basu","year":"2018","unstructured":"Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S et al (2018) A randomized phase 2 study of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 28(4):764\u2013772. https:\/\/doi.org\/10.1097\/IGC.0000000000001235","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"3_CR253","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ygyno.2020.06.493","volume":"158","author":"WK Huh","year":"2020","unstructured":"Huh WK, Brady WE, Fracasso PM, Dizon DS, Powell MA, Monk BJ et al (2020) Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol 158(3):562\u2013569. https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.493","journal-title":"Gynecol Oncol"},{"issue":"19","key":"3_CR254","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","volume":"25","author":"R Hassan","year":"2019","unstructured":"Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S et al (2019) Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res 25(19):5787\u20135798. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0070","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3_CR255","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1200\/JCO.2019.37.8_suppl.29","volume":"37","author":"EW Alley","year":"2019","unstructured":"Alley EW, Tanvetyanon T, Jahan TM, Gandhi L, Peikert T, Stevenson J et al (2019) A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM). J Clin Oncol 37(8):29. https:\/\/doi.org\/10.1200\/JCO.2019.37.8_suppl.29","journal-title":"J Clin Oncol"},{"issue":"10","key":"3_CR256","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM et al (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989\u20132003. https:\/\/doi.org\/10.1084\/jem.20101158","journal-title":"J Exp Med"},{"key":"3_CR257","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2019.00241","volume":"9","author":"S Di","year":"2019","unstructured":"Di S, Zhou M, Pan Z, Sun R, Chen M, Jiang H et al (2019) Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells. Front Oncol 9:241. https:\/\/doi.org\/10.3389\/fonc.2019.00241","journal-title":"Front Oncol"},{"issue":"11","key":"3_CR258","doi-asserted-by":"publisher","first-page":"7670","DOI":"10.4049\/jimmunol.181.11.7670","volume":"181","author":"SM Ngoi","year":"2008","unstructured":"Ngoi SM, Tovey MG, Vella AT (2008) Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha\/beta. J Immunol 181(11):7670\u20137680. https:\/\/doi.org\/10.4049\/jimmunol.181.11.7670","journal-title":"J Immunol"},{"issue":"11","key":"3_CR259","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nm.1887","volume":"14","author":"H Poeck","year":"2008","unstructured":"Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS et al (2008) 5\u2019-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14(11):1256\u20131263. https:\/\/doi.org\/10.1038\/nm.1887","journal-title":"Nat Med"},{"issue":"4","key":"3_CR260","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/jir.2007.0097","volume":"28","author":"JR Inglefield","year":"2008","unstructured":"Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA et al (2008) TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res 28(4):253\u2013263. https:\/\/doi.org\/10.1089\/jir.2007.0097","journal-title":"J Interferon Cytokine Res"},{"issue":"12","key":"3_CR261","doi-asserted-by":"publisher","first-page":"2100166","DOI":"10.1002\/advs.202100166","volume":"8","author":"J Mai","year":"2021","unstructured":"Mai J, Li Z, Xia X, Zhang J, Li J, Liu H et al (2021) Synergistic activation of antitumor immunity by a particulate therapeutic vaccine. Adv Sci (Weinh). 8(12):2100166. https:\/\/doi.org\/10.1002\/advs.202100166","journal-title":"Adv Sci (Weinh)."},{"issue":"5","key":"3_CR262","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41(5):843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019","journal-title":"Immunity"},{"issue":"12","key":"3_CR263","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.4049\/jimmunol.1401869","volume":"193","author":"J Klarquist","year":"2014","unstructured":"Klarquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM (2014) STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol 193(12):6124\u20136134. https:\/\/doi.org\/10.4049\/jimmunol.1401869","journal-title":"J Immunol"},{"issue":"3","key":"3_CR264","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.celrep.2019.09.089","volume":"29","author":"KE Sivick","year":"2019","unstructured":"Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH et al (2019) Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep 29(3):785\u2013789. https:\/\/doi.org\/10.1016\/j.celrep.2019.09.089","journal-title":"Cell Rep"},{"issue":"5","key":"3_CR265","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202(5):637\u2013650. https:\/\/doi.org\/10.1084\/jem.20050821","journal-title":"J Exp Med"},{"issue":"8","key":"3_CR266","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.4049\/jimmunol.176.8.4682","volume":"176","author":"A Le Bon","year":"2006","unstructured":"Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C et al (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176(8):4682\u20134689. https:\/\/doi.org\/10.4049\/jimmunol.176.8.4682","journal-title":"J Immunol"},{"issue":"4","key":"3_CR267","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI98047","volume":"128","author":"D Zamarin","year":"2018","unstructured":"Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM et al (2018) PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest 128(4):1413\u20131428. https:\/\/doi.org\/10.1172\/JCI98047","journal-title":"J Clin Invest"},{"issue":"3 Suppl 7","key":"3_CR268","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/sonc.2002.33078","volume":"29","author":"J Kirkwood","year":"2002","unstructured":"Kirkwood J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29(3 Suppl 7):18\u201326. https:\/\/doi.org\/10.1053\/sonc.2002.33078","journal-title":"Semin Oncol"},{"issue":"4","key":"3_CR269","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z et al (2019) Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178(4):933\u2013948. https:\/\/doi.org\/10.1016\/j.cell.2019.07.019","journal-title":"Cell"},{"issue":"6","key":"3_CR270","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C et al (2016) Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167(6):1540\u20131554. https:\/\/doi.org\/10.1016\/j.cell.2016.11.022","journal-title":"Cell"},{"key":"3_CR271","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","volume":"16","author":"GM Boukhaled","year":"2021","unstructured":"Boukhaled GM, Harding S, Brooks DG (2021) Opposing roles of type I interferons in cancer immunity. Annu Rev Pathol 16:167\u2013198. https:\/\/doi.org\/10.1146\/annurev-pathol-031920-093932","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"3_CR272","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","volume":"38","author":"LM Snell","year":"2017","unstructured":"Snell LM, McGaha TL, Brooks DG (2017) Type I interferon in chronic virus infection and cancer. Trends Immunol 38(8):542\u2013557. https:\/\/doi.org\/10.1016\/j.it.2017.05.005","journal-title":"Trends Immunol"},{"issue":"10","key":"3_CR273","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.celrep.2019.10.131","volume":"29","author":"A Magen","year":"2019","unstructured":"Magen A, Nie J, Ciucci T, Tamoutounour S, Zhao Y, Mehta M et al (2019) Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4(+) T Cells. Cell Rep 29(10):3019\u20133032. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.131","journal-title":"Cell Rep"},{"issue":"10","key":"3_CR274","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1084\/jem.20101664","volume":"207","author":"G Trinchieri","year":"2010","unstructured":"Trinchieri G (2010) Type I interferon: friend or foe? J Exp Med 207(10):2053\u20132063. https:\/\/doi.org\/10.1084\/jem.20101664","journal-title":"J Exp Med"},{"issue":"5","key":"3_CR275","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","volume":"186","author":"S Terawaki","year":"2011","unstructured":"Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T et al (2011) IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186(5):2772\u20132779. https:\/\/doi.org\/10.4049\/jimmunol.1003208","journal-title":"J Immunol"},{"issue":"1","key":"3_CR276","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s40425-019-0811-x","volume":"7","author":"MJ Reilley","year":"2019","unstructured":"Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA (2019) TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer 7(1):323. https:\/\/doi.org\/10.1186\/s40425-019-0811-x","journal-title":"J Immunother Cancer"},{"issue":"25","key":"3_CR277","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 Inhibition. N Engl J Med 377(25):2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"issue":"6230","key":"3_CR278","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172","journal-title":"Science"},{"issue":"1","key":"3_CR279","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20(1):25\u201339. https:\/\/doi.org\/10.1038\/s41577-019-0218-4","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"3_CR280","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni978","volume":"4","author":"A Le Bon","year":"2003","unstructured":"Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D et al (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4(10):1009\u20131015. https:\/\/doi.org\/10.1038\/ni978","journal-title":"Nat Immunol"},{"issue":"8","key":"3_CR281","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","volume":"28","author":"T Shekarian","year":"2017","unstructured":"Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C et al (2017) Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann Oncol 28(8):1756\u20131766. https:\/\/doi.org\/10.1093\/annonc\/mdx179","journal-title":"Ann Oncol"},{"issue":"14","key":"3_CR282","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F et al (2020) HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383(14):1340\u20131348. https:\/\/doi.org\/10.1056\/NEJMoa1917338","journal-title":"N Engl J Med"},{"issue":"25","key":"3_CR283","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99(25):16168\u201316173. https:\/\/doi.org\/10.1073\/pnas.242600099","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3_CR284","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/d41573-021-00031-9","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov 20(3):166. https:\/\/doi.org\/10.1038\/d41573-021-00031-9","journal-title":"Nat Rev Drug Discov"},{"key":"3_CR285","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","volume":"9","author":"S Guedan","year":"2018","unstructured":"Guedan S, Alemany R (2018) CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol 9:2460. https:\/\/doi.org\/10.3389\/fimmu.2018.02460","journal-title":"Front Immunol"},{"key":"3_CR286","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","volume":"9","author":"A Rosewell Shaw","year":"2018","unstructured":"Rosewell Shaw A, Suzuki M (2018) Oncolytic viruses partner with T-Cell therapy for solid tumor treatment. Front Immunol 9:2103. https:\/\/doi.org\/10.3389\/fimmu.2018.02103","journal-title":"Front Immunol"},{"issue":"11","key":"3_CR287","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH et al (2018) Magnitude of therapeutic sting activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 25(11):3074\u20133085. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.047","journal-title":"Cell Rep."},{"issue":"2","key":"3_CR288","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/sj.onc.1210904","volume":"27","author":"B Huang","year":"2008","unstructured":"Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2):218\u2013224. https:\/\/doi.org\/10.1038\/sj.onc.1210904","journal-title":"Oncogene"},{"key":"3_CR289","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.08.003","volume":"11","author":"AL Huff","year":"2018","unstructured":"Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M et al (2018) APOBEC3 ssserapy. Mol Ther Oncolytics. 11:1\u201313. https:\/\/doi.org\/10.1016\/j.omto.2018.08.003","journal-title":"Mol Ther Oncolytics."},{"issue":"3","key":"3_CR290","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-020-2399-y","volume":"11","author":"D Verzella","year":"2020","unstructured":"Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G et al (2020) Life, death, and autophagy in cancer: NF-kappaB turns up everywhere. Cell Death Dis 11(3):210. https:\/\/doi.org\/10.1038\/s41419-020-2399-y","journal-title":"Cell Death Dis"},{"issue":"10","key":"3_CR291","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1172\/JCI26322","volume":"115","author":"JL Luo","year":"2005","unstructured":"Luo JL, Kamata H, Karin M (2005) IKK\/NF-kappaB signaling: balancing life and death\u2013a new approach to cancer therapy. J Clin Invest 115(10):2625\u20132632. https:\/\/doi.org\/10.1172\/JCI26322","journal-title":"J Clin Invest"}],"container-title":["Cancer Treatment and Research","Cancer Immunotherapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-96376-7_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:16:49Z","timestamp":1700569009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-96376-7_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783030963750","9783030963767"],"references-count":291,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-96376-7_3","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"13 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}